Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release

Pharmacology and Therapeutics

Volumn 143, Issue 2, 2014, Pages 133-152

  Finberg, John P M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Affective disorders; Enzyme active site structure; Exocytotic and non exocytotic release; Neuroprotection; Parkinson's disease; Presynaptic inhibition

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BRAIN MONOAMINE; CATECHOLAMINE; CLORGYLINE; DOPAMINE; LADOSTIGIL; M30; MONOAMINE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NEUROTRANSMITTER; NORADRENALIN; PHENELZINE; RASAGILINE; REVERSIBLE MAO A INHIBITOR; REVERSIBLE MAO B INHIBITOR; SELEGILINE; SEROTONIN; TRANYLCYPROMINE; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; BIOGENIC AMINE; MONOAMINE OXIDASE INHIBITOR; NEUROPROTECTIVE AGENT;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CATECHOLAMINE METABOLISM; CENTRAL NERVOUS SYSTEM FUNCTION; CHEMICAL STRUCTURE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; EXOCYTOSIS; GENETIC DISORDER; HUMAN; NEUROMODULATION; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; BRAIN; CLASSIFICATION; METABOLISM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; BRAIN; DOPAMINE; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; NOREPINEPHRINE; PARKINSON DISEASE; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 84902545188     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.02.010     Document Type: Review

References (201)

1. E.D. Abercrombie, A.E. Bonatz, and M.J. Zigmond Effects of l-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats Brain Res 525 1 1990 36 44
2. M. Adli, M. Pilhatsch, M. Bauer, U. Koberle, R. Ricken, and G. Janssen et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression Pharmacopsychiatry 41 6 2008 252 257
3. G.K. Aghajanian, A.W. Graham, and M.H. Sheard Serotonin-containing neurons in brain: depression of firing by monoamine oxidase inhibitors Science 169 3950 1970 1100 1102
4. N. Alia-Klein, R.Z. Goldstein, A. Kriplani, J. Logan, D. Tomasi, and B. Williams et al. Brain monoamine oxidase A activity predicts trait aggression J Neurosci 28 19 2008 5099 5104
5. Y. Aluf, J. Vaya, S. Khatib, Y. Loboda, and J.P. Finberg Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway Neuropharmacology 65 2013 48 57
6. E. Alves, T. Summavielle, C.J. Alves, J.B. Custodio, E. Fernandes, and Bastos M. de Lourdes et al. Ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A Addict Biol 14 2 2009 185 193
7. E. Alves, T. Summavielle, C.J. Alves, J. Gomes-da-Silva, J.C. Barata, and E. Fernandes et al. Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescent rat brain mitochondria J Neurosci 27 38 2007 10203 10210
8. J.D. Amsterdam A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder J Clin Psychiatry 64 2 2003 208 214
9. R. Arai, K. Horiike, and Y. Hasegawa Dopamine-degrading activity of monoamine oxidase is not detected by histochemistry in neurons of the substantia nigra pars compacta of the rat Brain Res 812 1-2 1998 275 278
10. R. Arai, N. Karasawa, K. Kurokawa, H. Kanai, K. Horiike, and A. Ito Differential subcellular location of mitochondria in rat serotonergic neurons depends on the presence and the absence of monoamine oxidase type B Neuroscience 114 4 2002 825 835
11. F. Artigas, V. Perez, and E. Alvarez Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors Arch Gen Psychiatry 51 3 1994 248 251
12. N. Assareh, M.M. ElBatsh, C.A. Marsden, and D.A. Kendall The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat Pharmacol Biochem Behav 100 3 2012 506 512
13. A.J. Azzaro, C.M. Vandenberg, L.F. Blob, E.M. Kemper, M. Sharoky, and D.A. Oren et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects J Clin Pharmacol 46 8 2006 933 944
14. A.J. Azzaro, C.M. VanDenBerg, J. Ziemniak, E.M. Kemper, L.F. Blob, and B.J. Campbell Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers J Clin Pharmacol 47 8 2007 978 990
15. G.B. Baker, R.T. Coutts, K.F. McKenna, and R.L. Sherry-McKenna Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review J Psychiatry Neurosci 17 5 1992 206 214
16. G.B. Baker, J.T. Wong, J.M. Yeung, and R.T. Coutts Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA) J Affect Disord 21 3 1991 207 211
17. F.R. Bambico, N. Katz, G. Debonnel, and G. Gobbi Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex J Neurosci 27 43 2007 11700 11711
18. Y.D. Barac, O. Bar-Am, E. Liani, T. Amit, L. Frolov, and E. Ovcharenko et al. I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline PLoS One 7 11 2012 e47890
19. D.A. Barton, M.D. Esler, T. Dawood, E.A. Lambert, D. Haikerwal, and C. Brenchley et al. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy Arch Gen Psychiatry 65 1 2008 38 46
20. P. Bech, K.B. Stage, J.K. Larsen, P. Vestergaard, and L.F. Gram The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine J Affect Disord 140 3 2012 253 259
21. M. Bergstrom, G. Westerberg, G. Nemeth, M. Traut, G. Gross, and G. Greger et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography Eur J Clin Pharmacol 52 2 1997 121 128
22. P.R. Bieck, K.H. Antonin, G. Cremer, and C. Gleiter Tyramine pressor effects of CGP 11305A in comparison to tranylcypromine after prolonged treatment of human volunteers K.F. Tipton, P. Dostert, M. Strolin Benedetti, Monoamine oxidase and disease 1984 Academic Press London 505 513
23. C. Binda, E.M. Milczek, D. Bonivento, J. Wang, A. Mattevi, and D.E. Edmondson Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies Curr Top Med Chem 11 22 2011 2788 2796
24. C. Binda, P. Newton-Vinson, F. Hubalek, D.E. Edmondson, and A. Mattevi Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders Nat Struct Biol 9 1 2002 22 26
25. C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, and P. Salvati et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs J Med Chem 50 23 2007 5848 5852
26. T.K. Birkenhager, W.W. van den Broek, P.G. Mulder, J.A. Bruijn, and P. Moleman Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients J Clin Psychiatry 65 11 2004 1505 1510
27. W. Birkmayer, and P. Riederer Biochemical post-mortem findings in depressed patients J Neural Transm 37 2 1975 95 109
28. W. Birkmayer, P. Riederer, L. Ambrozi, and M.B. Youdim Implications of combined treatment with 'Madopar' and l-deprenil in Parkinson's disease. A long-term study Lancet 1 8009 1977 439 443
29. W. Birkmayer, P. Riederer, M.B. Youdim, and W. Linauer The potentiation of the anti akinetic effect after l-dopa treatment by an inhibitor of MAO-B, Deprenil J Neural Transm 36 3-4 1975 303 326
30. J.A. Bodkin, and J.D. Amsterdam Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients Am J Psychiatry 159 11 2002 1869 1875
31. D. Bonivento, E.M. Milczek, G.R. McDonald, C. Binda, A. Holt, and D.E. Edmondson et al. Potentiation of ligand binding through cooperative effects in monoamine oxidase B J Biol Chem 285 47 2010 36849 36856
32. M. Bortolato, K. Chen, and J.C. Shih Monoamine oxidase inactivation: from pathophysiology to therapeutics Adv Drug Deliv Rev 60 13-14 2008 1527 1533
33. M. Bortolato, S.C. Godar, S. Davarian, K. Chen, and J.C. Shih Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice Neuropsychopharmacology 34 13 2009 2746 2757
34. H.G. Brunner, M. Nelen, X.O. Breakefield, H.H. Ropers, and B.A. van Oost Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A Science 262 5133 1993 578 580
35. W.P. Burkard, E.P. Bonetti, M. Da Prada, J.R. Martin, P. Polc, and R. Schaffner et al. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A J Pharmacol Exp Ther 248 1 1989 391 399
36. S.P. Butcher, I.S. Fairbrother, J.S. Kelly, and G.W. Arbuthnott Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum J Neurochem 55 3 1990 981 988
37. N.T. Buu Modification of vesicular dopamine and norepinephrine by monoamine oxidase inhibitors Biochem Pharmacol 38 10 1989 1685 1692
38. C. Caccia, R. Maj, M. Calabresi, S. Maestroni, L. Faravelli, and L. Curatolo et al. Safinamide: from molecular targets to a new anti-Parkinson drug Neurology 67 7 Suppl. 2 2006 S18 S23
39. D. Caille, O.E. Bergis, C. Fankhauser, A. Gardes, R. Adam, and T. Charieras et al. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile J Pharmacol Exp Ther 277 1 1996 265 277
40. G.W. Carlile, R.M. Chalmers-Redman, N.A. Tatton, A. Pong, K.E. Borden, and W.G. Tatton Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer Mol Pharmacol 57 1 2000 2 12
41. K. Castagnoli, S.J. Steyn, G. Magnin, C.J. Van Der Schyf, I. Fourie, and A. Khalil et al. Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase Neurotox Res 4 2 2002 151 160
42. P. Celada, and F. Artigas Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat Naunyn Schmiedebergs Arch Pharmacol 347 6 1993 583 590
43. M.A. Cenci, K.E. Ohlin, and D. Rylander Plastic effects of l-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia Parkinsonism Relat Disord 15 Suppl. 3 2009 S59 S63
44. A. Clarke, F. Brewer, E.S. Johnson, N. Mallard, F. Hartig, and S. Taylor et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition J Neural Transm 110 11 2003 1241 1255
45. M.D. Cohen, J. Finberg, M. Dibner-Dunlap, S.N. Yuih, and M.D. Thames Effects of desipramine hydrochloride on peripheral sympathetic nerve activity Am J Physiol 258 4 Pt 2 1990 R876 R882
46. R.T. Coutts, A. Mozayani, T.J. Danielson, and G.B. Baker Tissue levels and some pharmacological properties of an acetylated metabolite of phenelzine in the rat J Pharm Sci 80 8 1991 765 767
47. P.W. Czoty, J.B. Justice Jr., and L.L. Howell Cocaine-induced changes in extracellular dopamine determined by microdialysis in awake squirrel monkeys Psychopharmacology (Berl) 148 3 2000 299 306
48. M. Da Prada, R. Kettler, W.P. Burkard, and W.E. Haefely Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats K.F. Tipton, P. Dostert, M. Strolin Benedetti, Monoamine oxidase and disease 1984 Academic press London 137 154
49. M. Da Prada, R. Kettler, H.H. Keller, W.P. Burkard, D. Muggli-Maniglio, and W.E. Haefely Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A J Pharmacol Exp Ther 248 1 1989 400 414
50. S.C. Daubner, T. Le, and S. Wang Tyrosine hydroxylase and regulation of dopamine synthesis Arch Biochem Biophys 508 1 2011 1 12
51. L. De Colibus, M. Li, C. Binda, A. Lustig, D.E. Edmondson, and A. Mattevi Three-dimensional structure of human monoamine oxidase A (MAO-A); relation to the structures of rat MAO-A and human MAO-B Proc Natl Acad Sci USA 102 36 2005 12684 12689
52. R.M. Denney, and C.B. Denney An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and B Pharmacol Ther 30 3 1985 227 258
53. D.A. Di Monte, L.E. DeLanney, I. Irwin, J.E. Royland, P. Chan, and M.W. Jakowec et al. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of l-DOPA-treated monkeys Brain Res 738 1 1996 53 59
54. D.E. Edmondson, C. Binda, and A. Mattevi Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B Arch Biochem Biophys 464 2 2007 269 276
55. D.E. Edmondson, C. Binda, J. Wang, A.K. Upadhyay, and A. Mattevi Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases Biochemistry 48 20 2009 4220 4230
56. D.E. Edmondson, A. Mattevi, C. Binda, M. Li, and F. Hubalek Structure and mechanism of monoamine oxidase Curr Med Chem 11 15 2004 1983 1993
57. G. Eisenhofer, I.J. Kopin, and D.S. Goldstein Catecholamine metabolism: a contemporary view with implications for physiology and medicine Pharmacol Rev 56 3 2004 331 349
58. A. Elkashef, P.J. Fudala, L. Gorgon, S.H. Li, R. Kahn, and N. Chiang et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence Drug Alcohol Depend 85 3 2006 191 197
59. I. Fagervall, and S.B. Ross A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain J Neurochem 47 2 1986 569 576
60. A.D. Feiger, K. Rickels, M.A. Rynn, D.L. Zimbroff, and D.S. Robinson Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial J Clin Psychiatry 67 9 2006 1354 1361
61. A. Ferrer, and F. Artigas Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain Eur J Pharmacol 263 3 1994 227 234
62. J.P. Finberg, and P.K. Gillman Selective inhibitors of monoamine oxidase Type B and the "cheese effect" M.B. Youdim, P. Riederer, International Review of Neurobiology Vol. 100 2011 Academic Press Burlington 169 190
63. J.P. Finberg, A. Gross, O. Bar-Am, R. Friedman, Y. Loboda, and M.B. Youdim Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and l-DOPA in the rat Br J Pharmacol 149 6 2006 647 656
64. J.P. Finberg, and M. Tenne Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens Br J Pharmacol 77 1 1982 13 21
65. J.P. Finberg, J. Wang, D.S. Goldstein, I.J. Kopin, and K.S. Bankiewicz Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of l-DOPA in hemiparkinsonian rats J Neurochem 65 3 1995 1213 1220
66. J.P. Finberg, and M.B. Youdim Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours Neuropharmacology 43 7 2002 1110 1118
67. F. Fornai, K. Chen, F.S. Giorgi, M. Gesi, M.G. Alessandri, and J.C. Shih Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study J Neurochem 73 6 1999 2434 2440
68. J.S. Fowler, J. Logan, A.J. Azzaro, R.M. Fielding, W. Zhu, and A.K. Poshusta et al. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157 Neuropsychopharmacology 35 3 2010 623 631
69. J.S. Fowler, N.D. Volkow, G.J. Wang, N. Pappas, J. Logan, and C. Shea et al. Brain monoamine oxidase A inhibition in cigarette smokers Proc Natl Acad Sci U S A 93 24 1996 14065 14069
70. J.S. Fowler, G.J. Wang, N.D. Volkow, D. Franceschi, J. Logan, and N. Pappas et al. Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence Am J Psychiatry 157 11 2000 1864 1866
71. D. Gallardo-Pujol, A. Andres-Pueyo, and A. Maydeu-Olivares MAOA genotype, social exclusion and aggression: an experimental test of a gene-environment interaction Genes Brain Behav 12 1 2013 140 145
72. P.K. Gillman The serotonin syndrome and its treatment J Psychopharmacol 13 1 1999 100 109
73. P.K. Gillman A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action Biol Psychiatry 59 11 2006 1046 1051
74. P.K. Gillman Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors J Clin Psychopharmacol 31 1 2011 66 74
75. P.K. Gillman, and I.M. Whyte Serotonin syndrome P. Hadad, S. Dursun, B. Deakin, Adverse syndromes and psychiatric drugs 2004 Oxford University Press Oxford 37 49
76. N. Ginovart, A.A. Wilson, J.H. Meyer, D. Hussey, and S. Houle [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats Synapse 47 2 2003 123 133
77. S. Glezer, and J.P. Finberg Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens Eur J Pharmacol 472 3 2003 173 177
78. J.F. Goldberg, and M.E. Thase Monoamine oxidase inhibitors revisited: what you should know J Clin Psychiatry 74 2 2013 189 191
79. A.R. Green, and M.B. Youdim Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration Br J Pharmacol 55 3 1975 415 422
80. G. Griebel, J. Stemmelin, and B. Scatton Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents Biol Psychiatry 57 3 2005 261 267
81. K. Guillem, C. Vouillac, M.R. Azar, L.H. Parsons, G.F. Koob, and M. Cador et al. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats J Neurosci 25 38 2005 8593 8600
82. K. Guillem, C. Vouillac, M.R. Azar, L.H. Parsons, G.F. Koob, and M. Cador et al. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats Eur J Neurosci 24 12 2006 3532 3540
83. K. Guillem, C. Vouillac, G.F. Koob, M. Cador, and L. Stinus Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion Biol Psychiatry 63 2 2008 158 163
84. K.A. Haberny, S.L. Walsh, D.H. Ginn, J.N. Wilkins, J.E. Garner, and D. Setoda et al. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline Drug Alcohol Depend 39 1 1995 55 62
85. M.L.C. Hare Tyramine oxidase: a new enzyme system in liver Biochem J 22 4 1928 968 979
86. P. Hashemi, E.C. Dankoski, R. Lama, K.M. Wood, P. Takmakov, and R.M. Wightman Brain dopamine and serotonin differ in regulation and its consequences Proc Natl Acad Sci U S A 109 29 2012 11510 11515
87. P. Hassanzadeh, and S. Rahimpour The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs Psychopharmacology (Berl) 215 1 2011 129 141
88. R.E. Heikkila, L. Manzino, F.S. Cabbat, and R.C. Duvoisin Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine by monoamine oxidase inhibitors Nature 311 5985 1984 467 469
89. M.N. Hill, W.S. Ho, C.J. Hillard, and B.B. Gorzalka Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents J Neural Transm 115 12 2008 1673 1679
90. N.H. Holford, T.W. Guentert, J. Dingemanse, and L. Banken Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor Br J Clin Pharmacol 37 5 1994 433 439
91. P. Huot, T.H. Johnston, J.B. Koprich, S.H. Fox, and J.M. Brotchie The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease Pharmacol Rev 65 1 2013 171 222
92. M. Iurlo, G. Leone, B. Schilstrom, L. Linner, G. Nomikos, and P. Hertel et al. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition Psychopharmacology (Berl) 159 1 2001 98 104
93. P. Jenner Oxidative stress in Parkinson's disease Ann Neurol 53 Suppl. 3 2003 S26 S36 (discussion S36-28)
94. P. Jenner Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease Neurology 63 7 Suppl. 2 2004 S13 S22
95. P. Jenner Preventing and controlling dyskinesia in Parkinson's disease - a view of current knowledge and future opportunities Mov Disord 23 Suppl. 3 2008 S585 S598
96. J.P. Johnston Some observations upon a new inhibitor of monoamine oxidase in brain tissue Biochem Pharmacol 17 7 1968 1285 1297
97. M. Katagi, M. Tatsuno, H. Tsutsumi, A. Miki, T. Kamata, and H. Nishioka et al. Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man Xenobiotica 32 9 2002 823 831
98. P.E. Keane, F. Chanoine, and M. Strolin Benedetti The effects of specific type A and B MAO inhibitors on reserpine-induced changes in brain dopamine and serum prolactin levels in the rat T.P. Singer, R.W. Von Korff, D.L. Murphy, Monoamine oxidase: structure, function and altered functions 1979 Academic Press New York 341 346
99. N. Kitanaka, J. Kitanaka, and M. Takemura Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum Neuroscience 130 2 2005 295 308
100. N. Kitanaka, J. Kitanaka, K. Watabe, and M. Takemura Low-dose pretreatment with clorgyline decreases the levels of 3-methoxy-4- hydroxyphenylglycol in the striatum and nucleus accumbens and attenuates methamphetamine-induced conditioned place preference in rats Neuroscience 165 4 2010 1370 1376
101. J. Knoll, Z. Ecseri, K. Kelemen, J. Nievel, and B. Knoll Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer Arch Int Pharmacodyn Ther 155 1 1965 154 164
102. J. Knoll, and K. Magyar Some puzzling pharmacological effects of monoamine oxidase inhibitors Adv Biochem Psychopharmacol 5 1972 393 408
103. I.J. Kopin Catecholamine metabolism: basic aspects and clinical significance Pharmacol Rev 37 4 1985 333 364
104. I.J. Kopin, J.E. Fischer, J. Musacchio, and W.D. Horst Evidence for a false neurochemical transmitter as a mechanism for the hypotensive effect of monoamine oxidase inhibitors Proc Natl Acad Sci U S A 52 1964 716 721
105. K. Laine, M. Anttila, R. Huupponen, O. Maki-Ikola, and E. Heinonen Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding Clin Neuropharmacol 23 1 2000 22 27
106. I. Lamensdorf, M.B. Youdim, and J.P. Finberg Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo J Neurochem 67 4 1996 1532 1539
107. A. Langeloh, H. Bonisch, and U. Trendelenburg The mechanism of the 3H-noradrenaline releasing effect of various substrates of uptake1: multifactorial induction of outward transport Naunyn Schmiedebergs Arch Pharmacol 336 6 1987 602 610
108. A. Langeloh, and U. Trendelenburg The mechanism of the 3H-noradrenaline releasing effect of various substrates of uptake1: role of monoamine oxidase and of vesicularly stored 3H-noradrenaline Naunyn Schmiedebergs Arch Pharmacol 336 6 1987 611 620
109. J.W. Langston, I. Irwin, E.B. Langston, and L.S. Forno Pargyline prevents MPTP-induced parkinsonism in primates Science 225 4669 1984 1480 1482
110. C. Lanteri, S.J. Hernandez Vallejo, L. Salomon, E.L. Doucet, G. Godeheu, and Y. Torrens et al. Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization J Neurosci 29 4 2009 987 997
111. J. Lauber, and P.C. Waldmeier Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS J Neural Transm 60 3-4 1984 247 264
112. Y. Lecrubier, and J.D. Guelfi Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression Acta Psychiatr Scand Suppl 360 1990 18 23
113. M.G. Lee, C. Wynder, D.M. Schmidt, D.G. McCafferty, and R. Shiekhattar Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications Chem Biol 13 6 2006 563 567
114. J.W. Lenders, G. Eisenhofer, N.G. Abeling, W. Berger, D.L. Murphy, and C.H. Konings et al. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes J Clin Invest 97 4 1996 1010 1019
115. M. Lohle, and H. Reichmann Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease BMC Neurol 11 2011 112
116. A. Lopez-Real, J. Rodriguez-Pallares, M.J. Guerra, and J.L. Labandeira-Garcia Localization and functional significance of striatal neurons immunoreactive to aromatic l-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models Brain Res 969 1-2 2003 135 146
117. S. Lotfipour, M.M. Arnold, D.J. Hogenkamp, K.W. Gee, J.D. Belluzzi, and F.M. Leslie The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition Neuropharmacology 61 1-2 2011 95 104
118. F. Lotufo-Neto, M. Trivedi, and M.E. Thase Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression Neuropsychopharmacology 20 3 1999 226 247
119. M. Lundblad, S. af Bjerken, M.A. Cenci, F. Pomerleau, G.A. Gerhardt, and I. Stromberg Chronic intermittent l-DOPA treatment induces changes in dopamine release J Neurochem 108 4 2009 998 1008
120. P. Lundquist, M. Roman, S. Syvanen, P. Hartvig, G. Blomquist, and M. Hammarlund-Udenaes et al. Effect on [11C]DASB binding after tranylcypromine- induced increase in serotonin concentration: positron emission tomography studies in monkeys and rats Synapse 61 6 2007 440 449
121. J. Ma, M. Yoshimura, E. Yamashita, A. Nakagawa, A. Ito, and T. Tsukihara Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors J Mol Biol 338 1 2004 103 114
122. E.M. MacKenzie, S.L. Grant, G.B. Baker, and P.L. Wood Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition Neurochem Res 33 3 2008 430 436
123. S.A. Mandel, Y. Sagi, and T. Amit Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway Neurochem Res 32 10 2007 1694 1699
124. J.J. Mann, S.F. Aarons, P.J. Wilner, J.G. Keilp, J.A. Sweeney, and T. Pearlstein et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor Arch Gen Psychiatry 46 1 1989 45 50
125. A. Marquet, K. Kupas, A. Johne, B. Astruc, A. Patat, and S. Krosser et al. The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial Clin Pharmacol Ther 92 4 2012 450 457
126. W. Maruyama, Y. Akao, M.C. Carrillo, K. Kitani, M.B. Youdium, and M. Naoi Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes Neurotoxicol Teratol 24 5 2002 675 682
127. D. Matveychuk, E. Nunes, N. Ullah, C.A. Velazquez-Martinez, E.M. Mackenzie, and G.B. Baker Comparison of phenelzine and geometric isomers of its active metabolite, beta-phenylethylidenehydrazine, on rat brain levels of amino acids, biogenic amine neurotransmitters and methylamine J Neural Transm 120 6 2013 987 996
128. N.B. Mercuri, M. Federici, S. Marinelli, and G. Bernardi Tranylcypromine, but not moclobemide, prolongs the inhibitory action of dopamine on midbrain dopaminergic neurons: an in vitro electrophysiological study Synapse 37 3 2000 216 221
129. J.H. Meyer, N. Ginovart, A. Boovariwala, S. Sagrati, D. Hussey, and A. Garcia et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression Arch Gen Psychiatry 63 11 2006 1209 1216
130. E.M. Milczek, C. Binda, S. Rovida, A. Mattevi, and D.E. Edmondson The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition FEBS J 278 24 2011 4860 4869
131. D.L. Murphy, S. Lipper, I.C. Campbell, L.F. Major, S. Slater, and M.S. Buchsbaum Comparative studies of MAO-A and MAO-B inhibitors in man T.P. Singer, R.W. Von Korff, D.L. Murphy, Monoamine oxidase: structure, function and altered functions 1979 Academic Press New York 457 475
132. M. Naoi, and W. Maruyama Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease Expert Rev Neurother 9 8 2009 1233 1250
133. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdere Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease Neurobiol Dis 41 2 2011 585 590
134. A.M. O'Carroll, C.J. Fowler, J.P. Phillips, I. Tobbia, and K.F. Tipton The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions Naunyn Schmiedebergs Arch Pharmacol 322 3 1983 198 202
135. S.O. Ogren, A.L. Ask, A.C. Holm, L. Florvall, L.O. Lindbrom, and J. Lundstrom et al. Biochemical and pharmacological properties of a new selective and reversible monoamine oxidase inhibitor, FLA 336 (+) M.B.H. Youdim, E.S. Paykel, Monoamine oxidase inhibitors - the state of the art 1981 Wiley Chichester 103 112
136. C.W. Olanow, O. Rascol, R. Hauser, P.D. Feigin, J. Jankovic, and A. Lang et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease N Engl J Med 361 13 2009 1268 1278
137. G.A. Ordway, J.T. Farley, G.E. Dilley, J.C. Overholser, H.Y. Meltzer, and E.K. Balraj et al. Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression Brain Res 847 1 1999 71 79
138. E.S. Paykel, P.S. West, P.R. Rowan, and R.R. Parker Influence of acetylator phenotype on antidepressant effects of phenelzine Br J Psychiatry 141 1982 243 248
139. J.P. Pepper, M.H. Baumann, M. Ayestas, and R.B. Rothman Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens Brain Res Mol Brain Res 87 2 2001 184 189
140. V. Perez, D. Puiigdemont, I. Gilaberte, E. Alvarez, and F. Artigas Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors J Clin Psychopharmacol 21 1 2001 36 45
141. E.N. Pothos, V. Davila, and D. Sulzer Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size J Neurosci 18 11 1998 4106 4118
142. H. Przuntek, B. Conrad, J. Dichgans, P.H. Kraus, P. Krauseneck, and G. Pergande et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa Eur J Neurol 6 2 1999 141 150
143. F. Radat, I. Berlin, O. Spreux-Varoquaux, S. Elatki, M. Ferreri, and A.J. Puech Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study Psychopharmacology (Berl) 127 4 1996 370 376
144. R. Raddatz, S.L. Savic, and S.M. Lanier Imidazoline binding domains on MAO-B. Localization and accessibility Ann N Y Acad Sci 881 1999 26 31
145. O. Rascol, D.J. Brooks, E. Melamed, W. Oertel, W. Poewe, and F. Stocchi et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial Lancet 365 9463 2005 947 954
146. O. Rascol, C.J. Fitzer-Attas, R. Hauser, J. Jankovic, A. Lang, and J.W. Langston et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes Lancet Neurol 10 5 2011 415 423
147. A. Remaury, R. Raddatz, C. Ordener, S. Savic, J.C. Shih, and K. Chen et al. Analysis of the pharmacological and molecular heterogeneity of I(2)-imidazoline-binding proteins using monoamine oxidase-deficient mouse models Mol Pharmacol 58 5 2000 1085 1090
148. G.P. Reynolds, J.D. Elsworth, K. Blau, M. Sandler, A.J. Lees, and G.M. Stern Deprenyl is metabolized to methamphetamine and amphetamine in man Br J Clin Pharmacol 6 6 1978 542 544
149. J.G. Richards, J. Saura, J.M. Luque, A.M. Cesura, J. Gottowik, and P. Malherbe et al. Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology J.P.M. Finberg, M.B.H. Youdim, P. Riederer, K.F. Tipton, MAO - the mother of all amine oxidases 1998 Springer-Verlag Vienna (pp.)
150. P. Riederer, and G. Laux MAO - inhibitors in Parkinson's disease Exp Neurobiol 20 1 2011 1 17
151. D.S. Robinson, T.B. Cooper, S.P. Jindal, J. Corcella, and T. Lutz
152. O. Sader-Mazbar, Y. Loboda, and J.P.M. Finberg Increased l-dopa-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation Br J Pharmacol 170 5 2013 999 1013
153. Y. Sagi, N. Drigues, and M.B. Youdim The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to l-dopa and l-tryptophan, in rats Br J Pharmacol 146 4 2005 553 560
154. L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia, and S. Dulawa et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 301 5634 2003 805 809
155. A.H. Schapira Safinamide in the treatment of Parkinson's disease Expert Opin Pharmacother 11 13 2010 2261 2268
156. A.H. Schapira, F. Stocchi, R. Borgohain, M. Onofrj, M. Bhatt, and P. Lorenzana et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease Eur J Neurol 20 2 2013 271 280
157. W.K. Schiffer, M. Azmoodeh, M. Gerasimov, N.D. Volkow, J.S. Fowler, and S.L. Dewey Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine Synapse 48 1 2003 35 38
158. D.M. Schmidt, and D.G. McCafferty trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1 Biochemistry 46 14 2007 4408 4416
159. O. Schmiedeberg Über das Verhältnis des Ammoniaks und der primären Monoaminbasen zur Harnstoffbildung im Tierkörper Arch Exp Pathol Pharmakol 8 1877 1 14
160. T. Sharp, S.E. Gartside, and V. Umbers Effects of co-administration of a monoamine oxidase inhibitor and a 5-HT1A receptor antagonist on 5-hydroxytryptamine cell firing and release Eur J Pharmacol 320 1 1997 15 19
161. R.L. Sherry, G. Rauw, K.F. McKenna, P.R. Paetsch, R.T. Coutts, and G.B. Baker Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine J Affect Disord 61 1-2 2000 23 29
162. J.C. Shih, J.B. Wu, and K. Chen Transcriptional regulation and multiple functions of MAO genes J Neural Transm 118 7 2011 979 986
163. K. Shioda, K. Nisijima, T. Yoshino, and S. Kato Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine Prog Neuropsychopharmacol Biol Psychiatry 28 4 2004 633 640
164. T.A. Slotkin, F.J. Seidler, and J.C. Ritchie Effects of aging and glucocorticoid treatment on monoamine oxidase subtypes in rat cerebral cortex: therapeutic implications Brain Res Bull 47 4 1998 345 348
165. J.T. Stewart Not all monoamine oxidase inhibitors are created equal J Am Geriatr Soc 55 11 2007 1890
166. D. Sulzer, and E.N. Pothos Regulation of quantal size by presynaptic mechanisms Rev Neurosci 11 2-3 2000 159 212
167. T. Tatsuta, N. Kitanaka, J. Kitanaka, Y. Morita, and M. Takemura Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats Neurochem Res 30 11 2005 1377 1385
168. W.G. Tatton, and R.M.E. Chalmers-Redman Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration Neurology 47 Supplement 3 1996 S171 S183
169. P. Teismann, K. Tieu, O. Cohen, D.K. Choi, D.C. Wu, and D. Marks et al. Pathogenic role of glial cells in Parkinson's disease Mov Disord 18 2 2003 121 129
170. P.F. Teychenne, D.B. Calne, P.J. Lewis, and L.J. Findley Interactions of levodopa with inhibitors of monoamine oxidase and l-aromatic amino acid decarboxylase Clin Pharmacol Ther 18 3 1975 273 277
171. D.M. Thomas, D.M. Francescutti-Verbeem, and D.M. Kuhn The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity J Neurochem 105 3 2008 605 616
172. D.M. Thomas, D.M. Francescutti-Verbeem, and D.M. Kuhn Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity J Neurochem 109 6 2009 1745 1755
173. J. Tong, J.H. Meyer, Y. Furukawa, I. Boileau, L.J. Chang, and A.A. Wilson et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies J Cereb Blood Flow Metab 33 6 2013 863 871
174. A.K. Upadhyay, P.P. Borbat, J. Wang, J.H. Freed, and D.E. Edmondson Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-d-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy Biochemistry 47 6 2008 1554 1566
175. J. Vaya, Y. Aluf, and J.P.M. Finberg Oxidative stress in Parkinson's disease N. Gadoth, H.H. Gobel, Oxidative stress and free radical damage in neurology 2012 Springer-Verlag New York 191 224
176. A.S. Villegier, L. Salomon, G. Blanc, G. Godeheu, J. Glowinski, and J.P. Tassin Irreversible blockade of monoamine oxidases reveals the critical role of 5-HT transmission in locomotor response induced by nicotine in mice Eur J Neurosci 24 5 2006 1359 1365
177. A.S. Villegier, L. Salomon, S. Granon, J.P. Changeux, J.D. Belluzzi, and F.M. Leslie et al. Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine Neuropsychopharmacology 31 8 2006 1704 1713
178. T. Vitalis, C. Fouquet, C. Alvarez, I. Seif, D. Price, and P. Gaspar et al. Developmental expression of monoamine oxidases A and B in the central and peripheral nervous systems of the mouse J Comp Neurol 442 4 2002 331 347
179. H.P. Volz, and C.H. Gleiter Monoamine oxidase inhibitors. A perspective on their use in the elderly Drugs Aging 13 5 1998 341 355
180. S.R. Wachtel, and E.D. Abercrombie l-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors J Neurochem 63 1 1994 108 117
181. P.C. Waldmeier, A. Delini-Stula, and L. Maitre Preferential deamination of dopamine by an A type monoamine oxidase in rat brain Naunyn Schmiedebergs Arch Pharmacol 292 1 1976 9 14
182. P.C. Waldmeier, A.E. Felner, and J. Lauber Reversible monoamine oxidase inhibitors: relation between effects on enzymatic activity measured ex vivo and on amine metabolism K.F. Tipton, P. Dostert, M. Strolin Benedetti, Monoamine oxidase and disease 1984 Academic press London 107 116
183. P.C. Waldmeier, A.E. Felner, and L. Maitre Long term effects on selective MAO inhibitors on MAO activity and amine metabolism M.B. Youdim, E.S. Paykel, Monoamine oxidase inhibitors: the state of the art 1981 Wiley Chichester 87 102
184. O. Weinreb, T. Amit, O. Bar-Am, and M.B. Youdim Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity Prog Neurobiol 92 3 2010 330 344
185. O. Weinreb, T. Amit, P. Riederer, M.B. Youdim, and S.A. Mandel Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease Int Rev Neurobiol 100 2011 127 149
186. M. Weinstock, E. Gorodetsky, R.H. Wang, A. Gross, O. Weinreb, and M.B. Youdim Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits Neuropharmacology 43 6 2002 999 1005
187. K.N. Westlund, T.J. Krakower, S.W. Kwan, and C.W. Abell Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord Brain Res 612 1-2 1993 221 230
188. S.A. Wiest, and M.I. Steinberg 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine Naunyn Schmiedebergs Arch Pharmacol 360 2 1999 209 216
189. J.M. Witkin, E.T. Tzavara, R.J. Davis, X. Li, and G.G. Nomikos A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders Trends Pharmacol Sci 26 12 2005 609 617
190. J.T. Wong, G.B. Baker, R.T. Coutts, and W.G. Dewhurst Long-lasting elevation of alanine in brain produced by the antidepressant phenelzine Brain Res Bull 25 1 1990 179 181
191. M. Yang, J.C. Culhane, L.M. Szewczuk, P. Jalili, H.L. Ball, and M. Machius et al. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine Biochemistry 46 27 2007 8058 8065
192. F. Yoneda, T. Moto, M. Sakae, H. Ohde, B. Knoll, and I. Miklya et al. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2- propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain Bioorg Med Chem 9 5 2001 1197 1212
193. M.B. Youdim Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline Exp Neurobiol 22 1 2013 1 10
194. M.B. Youdim, D. Edmondson, and K.F. Tipton The therapeutic potential of monoamine oxidase inhibitors Nat Rev Neurosci 7 4 2006 295 309
195. M.B. Youdim, and J.P. Finberg Monoamine oxidase inhibitor antidepressants D.G. Grahame-Smith, P.J. Cowen, Part 1: preclinical psychopharmacology 1983 Excerpta Medica Amsterdam 38 70
196. M.B. Youdim, and J. Finberg Monoamine oxidase inhibitor antidepressants D.G. Grahame-Smith, Psychopharmacology 2: Part 1: preclinical psychopharmacology 1985 Elsevier Amsterdam 35 70
197. M.B. Youdim, and J.P. Finberg New directions in monoamine oxidase A and B selective inhibitors and substrates Biochem Pharmacol 41 2 1991 155 162
198. M.B.H. Youdim, J.P.M. Finberg, and K.F. Tipton Monoamine Oxidase U. Trendelenburg, N. Weiner, Handbook of Experimental Pharmacology Vol. 90 1988 Springer-Verlag Berlin 119 192
199. M.B. Youdim, A. Gross, and J.P. Finberg Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B Br J Pharmacol 132 2 2001 500 506
200. P.H. Yu, and K.F. Tipton Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity Biochem Pharmacol 38 23 1989 4245 4251
201. R. Zimmer Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors Acta Psychiatr Scand Suppl 360 1990 81 83